Medical Devices · us
Robotic Arms Rise from the Operating Table: FDA Authorizes Johnson & Johnson’s OTTAVA for Market
This soft-tissue surgical robot integrates four robotic arms into the operating table, initially covering ten upper-abdominal procedures; the real test will be whether hospital adoption, team training, and clinical benefits can withstand everyday use.
Competition in surgical robotics is expanding from operational precision to how the entire operating room functions. The U.S. Food and Drug Administration (FDA), through the De Novo pathway, has authorized Johnson & Johnson’s OTTAVA robotic surgical system for market. Its most striking design feature is not an additional cart, but four robotic arms integrated directly into the operating table, in an effort to reduce equipment footprint and workflow disruptions caused by repositioning patients.
FDA records show that the applicant was Auris Health, part of Johnson & Johnson MedTech; the case number was DEN250068, received on December 18, 2025, and approved on July 21, 2026. OTTAVA was classified as a computer-controlled surgical instrument system, with the product code NAY. The De Novo process is generally used for novel moderate-risk medical devices that lack an appropriate existing classification, and it also establishes a regulatory benchmark for subsequent products of the same type.
This authorization covers ten general surgical procedures, including gastric bypass, gastrectomy, cholecystectomy, splenectomy, sleeve gastrectomy, small bowel resection, appendectomy, adhesiolysis, fundoplication, and hiatal hernia repair. In other words, OTTAVA has gained market access for multiple upper-abdominal procedures, rather than comprehensive authorization covering all soft-tissue surgery; inguinal hernia surgery remains in U.S. clinical trials.
The system allows the operating table and robotic arms to move in sync to support procedures spanning different abdominal regions, while preset positions assist with setup and stowage. It also connects to Johnson & Johnson’s digital platform, integrating educational content, surgical video, and data. The company claims that its footprint is 30% to 50% smaller than that of traditional boom-mounted or cart-based systems, but this comparison comes from the company’s internal assessment as of September 2025 and cannot be directly equated with shorter operating times, fewer complications, or better patient outcomes.
The market significance is that OTTAVA formally brings Johnson & Johnson into the soft-tissue surgical robotics competition long dominated by Intuitive Surgical. However, hospitals are purchasing more than hardware: surgeons, nursing staff, and instrument teams all require training, while operating-room scheduling, consumables supply, and maintenance systems must also be coordinated. Industry analysis therefore expects adoption to proceed in phases, and whether it can challenge established platforms in the short term will still depend on user experience and total cost.
Johnson & Johnson plans to initially introduce OTTAVA to a small number of U.S. customers, then gradually expand its indications and enter other markets. At this stage, publicly available information remains insufficient to compare its complication rates, conversion rates to open surgery, operating times, and cost-effectiveness with existing systems. FDA market authorization means that the system has cleared the regulatory threshold; its clinical and economic value must still be determined through subsequent research and real-world usage data.